Insider trading

Period: 120 months Stock: BBIO + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

234 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

234 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

234 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

234 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
234 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
234 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

234 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
7 Apr 2020
Kumar Neil CEO and President · indirect
Sold, plan not stated
$45.98K 1,805 at 25.48
0.1%
3 Apr 2020
Kumar Neil CEO and President · indirect
Sold, plan not stated 2×
$7.53K 300 at 25.09
0.0%
2 Apr 2020
Kumar Neil CEO and President · indirect
Sold, plan not stated
$395.10K 15,778 at 25.04
0.6%
1 Apr 2020
Kumar Neil CEO and President · indirect
Sold, plan not stated 4×
$1.63M 62,117 at 26.26
2.3%
1 Apr 2020
STEPHENSON BRIAN C See Remarks
Sold, plan not stated 3×
$191.61K 7,200 at 26.61
2.1%
1 Apr 2020
Sold, plan not stated 3×
$69.63K 2,585 at 26.94
1.5%
3 Mar 2020
Kumar Neil CEO and President · indirect
Sold, plan not stated 3×
$647.15K 20,047 at 32.28
0.8%
2 Mar 2020
Kumar Neil CEO and President · indirect
Sold, plan not stated 3×
$3.23M 99,953 at 32.28
3.6%
2 Mar 2020
STEPHENSON BRIAN C See Remark
Sold, plan not stated 3×
$348.54K 10,800 at 32.27
3.1%
2 Mar 2020
Sold, plan not stated 2×
$128.97K 3,975 at 32.44
2.3%
11 Feb 2020
Turtle Cameron See Remarks
Sold, plan not stated
$74.56K 2,000 at 37.28
16.9%
10 Feb 2020
HOMCY CHARLES J Chairman of Pharmaceuticals
Sold, plan not stated
$720.00K 20,000 at 36.00
1.5%
5 Feb 2020
Kumar Neil CEO and President · indirect
Sold, plan not stated
$1.08M 30,893 at 34.87
1.1%
4 Feb 2020
Kumar Neil See Remarks · indirect
Sold, plan not stated
$1.90M 54,951 at 34.55
1.9%
4 Feb 2020
STEPHENSON BRIAN C See Remarks
Sold, plan not stated
$171.69K 4,973 at 34.52
1.4%
3 Feb 2020
Kumar Neil See Remarks · indirect
Sold, plan not stated 2×
$1.19M 34,156 at 34.93
1.2%
3 Feb 2020
STEPHENSON BRIAN C See Remarks
Sold, plan not stated
$203.38K 5,827 at 34.90
1.6%
3 Feb 2020
Sold, plan not stated
$138.73K 3,975 at 34.90
2.2%
14 Jan 2020
HOMCY CHARLES J Chairman of Pharmaceuticals
Sold, plan not stated
$350.00K 10,000 at 35.00
0.7%
8 Jan 2020
Turtle Cameron See Remarks
Sold, plan not stated 2×
$440.21K 12,807 at 34.37
56.6%
Sold half or more
3 Jan 2020
Kumar Neil See Remarks · indirect
Sold, plan not stated 2×
$2.70M 83,939 at 32.20
2.8%
3 Jan 2020
STEPHENSON BRIAN C See Remarks
Sold, plan not stated 2×
$117.44K 3,636 at 32.30
1.0%
3 Jan 2020
Sold, plan not stated 2×
$11.57K 358 at 32.33
0.2%
2 Jan 2020
Kumar Neil See Remarks · indirect
Sold, plan not stated 4×
$1.20M 36,061 at 33.26
1.2%
2 Jan 2020
STEPHENSON BRIAN C See Remarks
Sold, plan not stated 4×
$238.24K 7,164 at 33.26
1.9%
2 Jan 2020
Sold, plan not stated 3×
$120.29K 3,617 at 33.26
2.0%
30 Dec 2019
MCCORMICK FRANK Chairman of Oncology
Sold, plan not stated 2×
$614.01K 17,150 at 35.80
1.3%
27 Dec 2019
MCCORMICK FRANK Chairman of Oncology
Sold, plan not stated 8×
$3.14M 82,850 at 37.92
6.1%
1 Jul 2019
KKR Genetic Disorder L.P. 10% owner · indirect
Bought
$45.00M 2,647,100 at 17.00
7.7%
First buy on file
1 Jul 2019
STEPHENSON BRIAN C See Remark
Bought
$943.50K 55,500 at 17.00
17.7%
First buy on file
1 Jul 2019
Sinha Uma Chief Scientific Officer
Bought
$238.00K 14,000 at 17.00
opened
First buy on file
1 Jul 2019
Bought
$119.00K 7,000 at 17.00
4.0%
First buy on file
27 Jun 2019
VIKING GLOBAL PERFORMANCE LLC 10% owner · indirect
Bought
$80.00M 4,705,900 at 17.00
21.5%
First buy on file
27 Jun 2019
VIKING GLOBAL INVESTORS LP 10% owner · indirect
Bought
$80.00M 4,705,900 at 17.00
21.5%
First buy on file
Showing 201–234 of 234. ← Newer Page 5 of 5